Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Identification of side arm-modified DOTA scaffolds as multi-site binding ligands for cancer cells over normal cells.

Rustagi V, Udugamasooriya DG.

Bioorg Med Chem Lett. 2019 Oct 1;29(19):126619. doi: 10.1016/j.bmcl.2019.08.023. Epub 2019 Aug 12.

PMID:
31431362
2.

Converting a weaker ATP-binding site inhibitor into a potent hetero-bivalent ligand by tethering to a unique peptide sequence derived from the same kinase.

Kedika SR, Udugamasooriya DG.

Org Biomol Chem. 2018 Sep 11;16(35):6443-6449. doi: 10.1039/c8ob01406j.

PMID:
30140808
3.

A mini-library system to investigate non-essential residues of lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1.

Shukla SP, Udugamasooriya DG.

Medchemcomm. 2017 Dec 1;8(12):2208-2215. doi: 10.1039/C7MD00372B. Epub 2017 Oct 24.

4.

A unique mid-sequence linker used to multimerize the lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1.

Shukla SP, Manarang JC, Udugamasooriya DG.

Eur J Med Chem. 2017 Sep 8;137:1-10. doi: 10.1016/j.ejmech.2017.05.040. Epub 2017 May 19.

5.

A comprehensive lipid binding and activity validation of a cancer-specific peptide-peptoid hybrid PPS1.

Desai TJ, Udugamasooriya DG.

Biochem Biophys Res Commun. 2017 Apr 29;486(2):545-550. doi: 10.1016/j.bbrc.2017.03.083. Epub 2017 Mar 18.

6.

On-bead combinatorial synthesis and imaging of europium(III)-based paraCEST agents aids in identification of chemical features that enhance CEST sensitivity.

Singh J, Rustagi V, Zhang S, Sherry AD, Udugamasooriya DG.

Magn Reson Chem. 2017 Aug;55(8):747-753. doi: 10.1002/mrc.4588. Epub 2017 Mar 24.

7.

Identification of the minimum pharmacophore of lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1D1.

Singh J, Shukla SP, Desai TJ, Udugamasooriya DG.

Bioorg Med Chem. 2016 Sep 15;24(18):4470-4477. doi: 10.1016/j.bmc.2016.07.045. Epub 2016 Jul 21.

8.

Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.

Desai TJ, Toombs JE, Minna JD, Brekken RA, Udugamasooriya DG.

Oncotarget. 2016 May 24;7(21):30678-90. doi: 10.18632/oncotarget.8929.

9.

Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells.

Matharage JM, Minna JD, Brekken RA, Udugamasooriya DG.

ACS Chem Biol. 2015 Dec 18;10(12):2891-9. doi: 10.1021/acschembio.5b00592. Epub 2015 Oct 28.

10.

On-Bead Two-Color (OBTC) Cell Screen for Direct Identification of Highly Selective Cell Surface Receptor Ligands.

Udugamasooriya DG, Kodadek T.

Curr Protoc Chem Biol. 2012 Mar;4:35-48. Epub 2012 Mar 1.

11.

Development of homomultimers and heteromultimers of lung cancer-specific peptoids.

Hooks JC, Matharage JP, Udugamasooriya DG.

Biopolymers. 2011;96(5):567-77.

12.

On-bead combinatorial synthesis and imaging of chemical exchange saturation transfer magnetic resonance imaging agents to identify factors that influence water exchange.

Napolitano R, Soesbe TC, De León-Rodríguez LM, Sherry AD, Udugamasooriya DG.

J Am Chem Soc. 2011 Aug 24;133(33):13023-30. doi: 10.1021/ja201123f. Epub 2011 Jul 27.

13.

MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting.

De León-Rodríguez LM, Lubag A, Udugamasooriya DG, Proneth B, Brekken RA, Sun X, Kodadek T, Dean Sherry A.

J Am Chem Soc. 2010 Sep 22;132(37):12829-31. doi: 10.1021/ja105563a.

14.

GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.

Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA.

BMC Cancer. 2010 Jul 30;10:397. doi: 10.1186/1471-2407-10-397.

15.

Potent and selective photo-inactivation of proteins with peptoid-ruthenium conjugates.

Lee J, Udugamasooriya DG, Lim HS, Kodadek T.

Nat Chem Biol. 2010 Apr;6(4):258-60. doi: 10.1038/nchembio.333. Epub 2010 Mar 14.

16.

Isolation of antagonists of antigen-specific autoimmune T cell proliferation.

Gocke AR, Udugamasooriya DG, Archer CT, Lee J, Kodadek T.

Chem Biol. 2009 Nov 25;16(11):1133-9. doi: 10.1016/j.chembiol.2009.10.011.

17.

Recognition of lysine-rich peptide ligands by murine cortactin SH3 domain: CD, ITC, and NMR studies.

Rubini C, Ruzza P, Spaller MR, Siligardi G, Hussain R, Udugamasooriya DG, Bellanda M, Mammi S, Borgogno A, Calderan A, Cesaro L, Brunati AM, Donella-Deana A.

Biopolymers. 2010;94(3):298-306. doi: 10.1002/bip.21350.

PMID:
19921743
18.

Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA.

PLoS One. 2009 Nov 3;4(11):e7669. doi: 10.1371/journal.pone.0007669.

19.

Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth.

Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, Wang L, Udugamasooriya DG, Memic A, Rupasinghe CN, Baretton GB, Aust DE, Langer S, Datta K, Simons M, Spaller MR, Mukhopadhyay D.

Clin Cancer Res. 2009 Jun 15;15(12):4095-103. doi: 10.1158/1078-0432.CCR-08-2837. Epub 2009 Jun 9. Erratum in: Clin Cancer Res. 2009 Jul 15;15(14):4786. Rupashinghe, Chamila N [corrected to Rupasinghe, Chamila N].

20.

The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues.

Udugamasooriya DG, Dunham G, Ritchie C, Brekken RA, Kodadek T.

Bioorg Med Chem Lett. 2008 Nov 15;18(22):5892-4. doi: 10.1016/j.bmcl.2008.07.023. Epub 2008 Jul 10.

21.

A chemical library approach to organic-modified peptide ligands for PDZ domain proteins: a synthetic, thermodynamic and structural investigation.

Udugamasooriya DG, Sharma SC, Spaller MR.

Chembiochem. 2008 Jul 2;9(10):1587-9. doi: 10.1002/cbic.200800126. No abstract available.

22.

A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site.

Udugamasooriya DG, Ritchie C, Brekken RA, Kodadek T.

Bioorg Med Chem. 2008 Jun 15;16(12):6338-43. doi: 10.1016/j.bmc.2008.05.015. Epub 2008 May 9.

23.

A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity.

Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T.

J Am Chem Soc. 2008 Apr 30;130(17):5744-52. doi: 10.1021/ja711193x. Epub 2008 Apr 2.

PMID:
18386897
24.

Use of peptide analogue diversity library beads for increased depth of proteomic analysis: application to cerebrospinal fluid.

Shores KS, Udugamasooriya DG, Kodadek T, Knapp DR.

J Proteome Res. 2008 May;7(5):1922-31. doi: 10.1021/pr7006889. Epub 2008 Mar 22.

PMID:
18357977
25.

Conformational constraint in protein ligand design and the inconsistency of binding entropy.

Udugamasooriya DG, Spaller MR.

Biopolymers. 2008 Aug;89(8):653-67. doi: 10.1002/bip.20983.

PMID:
18335423

Supplemental Content

Loading ...
Support Center